In Vivo Topical

RNA Transfection Kit

Satreda LNP8003

A New Standard for Localized RNA Delivery

The SatredaLNP 8003 represents a breakthrough in precise, localized RNA delivery, designed to meet the growing demand for targeted transfection in tissues and organs beyond systemic reach. Built upon Satreda’s next-generation in vivo LNP platform, LNP8003 employs advanced lipid formulations and personalized targeting ligand designs to control nanoparticle biodistribution with exceptional accuracy. This enables RNA to be delivered exactly where it is needed — at the injection site — maximizing therapeutic impact while minimizing off-target effects.

Flexible and Ready-to-Use Local Delivery Solution

Developed as a ready-to-use local RNA delivery kit, LNP8003 simplifies complex in vivo workflows by enabling rapid RNA encapsulation within just one minute, compared to the 10+ hours or multi-day processes required by conventional methods. Its ethanol-free, biodegradable lipid system ensures biocompatibility and eliminates the risks of irritation, hemolysis, or neurotoxicity. The kit is optimized for a range of administration routes — including intratumoral (IT), intramuscular (IM), and intradermal (ID) injections — allowing researchers to choose the most effective method for their experimental goals.

High Precision and Local Enrichment

LNP8003 achieves over 90% local RNA enrichment at the injection site, an achievement that far surpasses conventional delivery systems. This concentration of RNA enables enhanced gene expression and silencing efficiency within the targeted tissue while preventing unwanted diffusion to other organs. Such precise control over RNA biodistribution ensures that experiments maintain high specificity and reproducibility — critical factors for both preclinical studies and translational applications.

Safe, Ethanol-Free, and Biocompatible

Safety and consistency are built into every component of LNP8003. Its biodegradable lipid materials provide exceptional biocompatibility, while the absence of ethanol and organic solvents ensures a gentle formulation that avoids vascular or neural irritation. The result is a high-performance yet low-toxicity transfection system suitable for sensitive tissues and precision medicine research.

Empowering Precision Medicine and Gene Therapy

By combining high efficiency, precise localization, flexible administration, and superior safety, LNP8003 delivers a next-generation solution for localized RNA therapy, vaccine delivery, and gene regulation. Whether used in tumor-targeted therapy, muscle-specific expression, or dermal gene studies, this kit empowers scientists to explore new frontiers in gene editing, targeted therapeutics, and personalized medicine — all with the simplicity of a one-minute, ready-to-use system.

Demonstrated Performance in Multiple Models

Validated across multiple delivery routes, LNP8003 consistently demonstrates remarkable tissue-specific expression and localization:

• Intratumoral (IT) Delivery: Up to 98% of mRNA fluorescence localized within solid tumor tissue six hours post-injection, making it ideal for oncology and tumor microenvironment research.

• Intramuscular (IM) Delivery: Achieves 97% expression of mRNA and 93% siRNA accumulation in muscle tissue, with negligible distribution to heart, liver, spleen, lungs, or kidneys — making it an excellent tool for vaccine development or localized gene modulation.

• Intradermal (ID) Delivery: Delivers 97% mRNA expression precisely to skin tissue, supporting gene regulation studies and dermatological applications.

• Intratumoral injection of Fluc-mRNA (10µg/mouse), 6-hour distribution.